CY1122829T1 - Φαρμακευτικη συνθεση για νευροπαθητικο πονο - Google Patents

Φαρμακευτικη συνθεση για νευροπαθητικο πονο

Info

Publication number
CY1122829T1
CY1122829T1 CY20201100232T CY201100232T CY1122829T1 CY 1122829 T1 CY1122829 T1 CY 1122829T1 CY 20201100232 T CY20201100232 T CY 20201100232T CY 201100232 T CY201100232 T CY 201100232T CY 1122829 T1 CY1122829 T1 CY 1122829T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
neuropathic pain
formulation
composition
palmitoylethanolamide
Prior art date
Application number
CY20201100232T
Other languages
English (en)
Inventor
Singh Ankit Shyam
Mishra Vedprakash
Tongra Neelima
Original Assignee
Frimline Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frimline Private Limited filed Critical Frimline Private Limited
Publication of CY1122829T1 publication Critical patent/CY1122829T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα δήλωση περιγράφει φαρμακευτική σύνθεση/σκεύασμα για χρήση στον έλεγχο νευροπαθητικού πόνου. H σύνθεση/σκεύασμα περιέχει Παλμιτοϋλαιθανολαμίδιο (ΡΕΑ) και ένα ή περισσότερα φυσικά συστατικά. Επίσης, η δήλωση παρέχει διάφορα σκευάσματα και μεθόδους παρασκευής αυτών.
CY20201100232T 2017-07-05 2020-03-16 Φαρμακευτικη συνθεση για νευροπαθητικο πονο CY1122829T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721023668 2017-07-05

Publications (1)

Publication Number Publication Date
CY1122829T1 true CY1122829T1 (el) 2021-05-05

Family

ID=61691848

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100232T CY1122829T1 (el) 2017-07-05 2020-03-16 Φαρμακευτικη συνθεση για νευροπαθητικο πονο

Country Status (18)

Country Link
US (1) US20190008806A1 (el)
EP (1) EP3424499B1 (el)
CA (1) CA2999030C (el)
CY (1) CY1122829T1 (el)
DK (1) DK3424499T3 (el)
EA (1) EA035667B1 (el)
ES (1) ES2776879T3 (el)
HR (1) HRP20200328T1 (el)
LT (1) LT3424499T (el)
ME (1) ME03680B (el)
MY (1) MY172113A (el)
PH (1) PH12018000077A1 (el)
PL (1) PL3424499T3 (el)
PT (1) PT3424499T (el)
RS (1) RS60127B1 (el)
SG (1) SG10201802129QA (el)
SI (1) SI3424499T1 (el)
UA (1) UA122080C2 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370409A1 (en) 2021-05-04 2022-11-24 Janssen Pharmaceuticals, Inc. Compositions And Methods For The Treatment Of Depression
WO2023133555A2 (en) * 2022-01-10 2023-07-13 Zilker Sciences Llc Palmitoylethanolamide treatment for covid-19-related inflammation
US20230277500A1 (en) * 2022-03-07 2023-09-07 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
TW202345796A (zh) 2022-03-07 2023-12-01 美商健生醫藥公司 阿替卡普蘭（ａｔｉｃａｐｒａｎｔ）之形式
IT202200017820A1 (it) * 2022-08-30 2024-03-01 Unifarco S P A Compressa nutraceutica comprendente palmitoiletanolamide
WO2024055006A2 (en) * 2022-09-09 2024-03-14 The Regents Of The University Of California Compositions for preventing transition from acute to chronic pain

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598294C (en) * 2005-02-17 2011-10-18 Astellas Pharma Inc. Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
WO2008030752A2 (en) * 2006-09-07 2008-03-13 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
JP2011523959A (ja) * 2008-06-11 2011-08-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｆａａｈの阻害剤として有用なイミダゾール誘導体
PL2334202T3 (pl) * 2008-09-04 2012-04-30 Cargill Inc Tabletkowanie erytrytolu
PT2796129E (pt) * 2009-09-07 2015-10-13 Epitech Group S P A Composição contendo palmitoiletanolamida ultramicronizada
ES2648188T3 (es) * 2012-02-17 2017-12-29 Epitech Group S.P.A. Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias
NL2014464B1 (en) * 2015-03-16 2017-01-13 Vanderbilt Science Holding Ltd Composition for use in the treatment of neuropathic pain.
WO2016183134A1 (en) * 2015-05-12 2016-11-17 Cutting Edge Medical Solutions, Llc Palmitoylethanolamide compositions
ITUB20153066A1 (it) * 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea

Also Published As

Publication number Publication date
PH12018000077B1 (en) 2019-01-21
PL3424499T3 (pl) 2020-06-29
CA2999030C (en) 2019-10-29
PT3424499T (pt) 2020-03-31
ME03680B (me) 2020-10-20
EA201891337A2 (ru) 2019-01-31
EA035667B1 (ru) 2020-07-23
CA2999030A1 (en) 2019-01-05
US20190008806A1 (en) 2019-01-10
RS60127B1 (sr) 2020-05-29
HRP20200328T1 (hr) 2020-07-24
SG10201802129QA (en) 2019-02-27
BR102018013710A2 (pt) 2019-01-22
LT3424499T (lt) 2020-03-25
EP3424499B1 (en) 2019-12-25
EP3424499A1 (en) 2019-01-09
DK3424499T3 (da) 2020-03-23
MY172113A (en) 2019-11-14
ES2776879T3 (es) 2020-08-03
PH12018000077A1 (en) 2019-01-21
EA201891337A3 (ru) 2019-05-31
UA122080C2 (uk) 2020-09-10
SI3424499T1 (sl) 2020-06-30

Similar Documents

Publication Publication Date Title
CY1122829T1 (el) Φαρμακευτικη συνθεση για νευροπαθητικο πονο
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
AR114780A1 (es) Formulaciones estables de inmunoconjugado anti-cd79b
CL2019003397A1 (es) Inhibidores pirazólicos de magl.
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
PH12020550217A1 (en) Nutrient-spore formulations and uses thereof
ZA202102816B (en) High concentration protein formulation
MX2021014806A (es) Composiciones para el cuidado bucal y sus usos.
MY186286A (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
EP3829643C0 (en) SYNERGISTIC COOPERATIVE COMPOSITIONS FOR SOFT TISSUE AUGMENTATION, DRUG DELIVERY AND RELATED AREAS
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
PL424007A1 (pl) Kompozycja zawierająca mieszaninę ekstraktów roślinnych
PL413921A1 (pl) Zestaw farmaceutyczny oraz zastosowanie erytropoetyny oraz inhibitora kinazy Brutona